FindTrial
Sign In

Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen

DRUG7 trials

Sponsors

Novo Nordisk A/S, Region Hovedstaden, Region Midtjylland, Trinity College Dublin, Clinical Pharmacology, Department of

Conditions

AdipositasAlcohol Use DisorderCardiovascular disorders: Hypertension and ObesityNon-alcoholic Fatty Liver DiseaseNon-alcoholic steatohepatitis (NASH)ObesityObesity and overweight

Phase 2

Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?
CompletedCTIS2023-503371-25-00
Region HovedstadenAlcohol Use Disorder
Start: 2023-06-08End: 2025-09-08Target: 108Updated: 2025-07-08

Phase 3

Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight
Active, not recruitingCTIS2022-502922-41-00
Novo Nordisk A/SObesity and overweight
Start: 2023-07-03Target: 86Updated: 2025-11-03
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
Active, not recruitingCTIS2023-506962-30-00
Novo Nordisk A/SNon-alcoholic steatohepatitis (NASH)
Start: 2021-03-29Target: 219Updated: 2025-11-11
Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.
RecruitingCTIS2024-513958-29-00
Trinity College DublinCardiovascular disorders: Hypertension and Obesity
Start: 2025-04-24Target: 50Updated: 2025-11-10

Phase 4

Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease
Active, not recruitingCTIS2023-506300-12-00
Region MidtjyllandNon-alcoholic Fatty Liver Disease, Obesity
Start: 2023-12-18Target: 24Updated: 2025-04-25
Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c. 2.4 mg Once-weekly
Active, not recruitingCTIS2023-508055-40-00
Novo Nordisk A/SObesity
Start: 2025-02-18Target: 309Updated: 2025-12-14
The GOAL study: GLP-1 receptor agonist treatment for Adolescents with Obesity secondary to Antipsychotic Medication - A feasibility study
RecruitingCTIS2024-517471-21-02
Clinical Pharmacology, Department ofAdipositas
Start: 2025-06-24Target: 34Updated: 2025-05-02

Related Papers

Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)
BMJ Open2025-01-018 citations